Information Library
Clinical and marketing materials - Phase IIIB/IV
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Emerging Markets
September 29, 2009
If you’re looking for new ways to bring development costs down, you may be considering the advantages of conducting clinical trials in emerging markets. -
Post-Marketing Commitment Study
June 30, 2009
Quintiles developed creative and effective solutions to deliver quality data, cost efficiently and ahead of schedule. -
Patient Registries: A Taxonomy for the Design, Development and Implementation
June 25, 2009
Recommendations from the ISPOR Patient Registry Classification, Strategy & Design Working Group, Team 2, for developing standard language for the characterization, classification, strategy, design, and execution of patient registries to generate data for outcomes research purposes. -
Early phase strategies
June 15, 2009
Web cast about Early Phase Strategies. -
Oversight Group Management Services
April 16, 2009
Quintiles provides a high level of experience, expertise and customer service to the entire clinical trial process. This is especially true for the oversight group management service, known as CEVA. -
Risk Mitigation Programs
April 16, 2009
Risk mitigation measures can help keep valuable drugs on the market, even when their safety profile includes adverse events that might negatively affect the benefit risk balance. -
Risk Assessment & Strategy
April 16, 2009
Quintiles benefit risk analysis can help you anticipate potential regulatory concerns and highlight the benefit side of your drug’s benefit risk profile. -
Phase IIIb/IV Studies
April 16, 2009
New, more efficient delivery models help meet the increasing demands of Phase IIIB/IV Studies. -
Late Phase and Safety Services
April 10, 2009
Recent and pending regulatory changes have created an atmosphere of watchful waiting throughout the industry. While it may seem premature to initiate post-marketing studies to collect more “intelligent” safety data, Quintiles Late Phase & Safety Services anticipates that the need for expanded studies will soon spread.
Page 1 of 1 (9 items)